Angiopoietins and non-vascular endothelial growth factor antiangiogenic targets in advanced renal cell carcinoma

Cancer Journal (United States)

Volumn 19, Issue 4, 2013, Pages 307-310

  Richey, Stephen L ^a   Hutson, Thomas E ^b  

^a Texas Oncology Fort Worth ^*  (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

angiopoietin; antiangiogenesis; fibroblast growth factor; platelet derived growth factor; Renal cell carcinoma; vascular disrupting agents

Indexed keywords

6 METHOXY 2 METHYL 3 (3,4,5 TRIMETHOXYBENZOYL)BENZOFURAN 7 YL PHOSPHATE DISODIUM; ANGIOPOIETIN; AXITINIB; BEVACIZUMAB; BRIVANIB; BRIVANIB ALANINATE; DOVITINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; MAMMALIAN TARGET OF RAPAMYCIN; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; REGORAFENIB; SORAFENIB; SUNITINIB; TREBANANIB; VASCULAR TARGETING AGENT; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANEMIA; ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ASTHENIA; BLOOD VESSEL PERMEABILITY; CANCER SURVIVAL; CELL PROLIFERATION; COLON CANCER; COUGHING; DIARRHEA; DRUG EFFICACY; FATIGUE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; ORAL MUCOSITIS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; REVIEW; SIGNAL TRANSDUCTION; SINUS BRADYCARDIA; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84880945756     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31829d5d15     Document Type: Review

References (46)

1. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688-696.
2. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
3. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J ClinOncol. 2008;26:5422-5428.
4. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
5. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061-1068.
6. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356: 2271-2281.
7. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931-1939.
8. Shim WS, Ho IA, Wong PE. Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res. 2007;5:655-665.
9. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55-60.
10. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGFdependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA. 2002;99:11205-11210.
11. Currie MJ, Gunningham SP, Turner K, et al. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von HippelYLindau gene and hypoxia. J Pathol. 2002;198:502-510.
12. Yamakawa M, Liu LX, Belanger AJ, et al. Expression of angiopoietins in renal epithelial and clear cell carcinoma cells: regulation by hypoxia and participation in angiogenesis. Am J Physiol Renal Physiol. 2004;287:F649-F657.
13. Bullock AJ, Zhang L, O'Neill AM, et al. Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC). J Clin Oncol (Meeting Abstr). 2010;28(suppl 15): 4630.
14. Rini B, Szczylik C, Tannir NM, et al. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer. 2012;118:6152-6161.
15. Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol. 2012; 30:362-371.
16. Rosen LS, Mendelson DS, Cohen RB, et al. First-in-human doseescalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2. ASCO (Meeting Abstr). 2010;28(suppl 15):2524.
17. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245-255.
18. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303-312.
19. Eisen T, Joensuu H, Nathan PD, et al. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol. 2012;13:1055-1062.
20. Javerzat S., Auguste P, Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol Med. 2002;8:483-489.
21. Rusnati M, Presta M. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr Pharm Des. 2007;13:2025-2044.
22. Presta M, Dell'era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005;16:159-178.
23. Tsimafeyeu I, Demidov L, Stepanova E, et al. Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma. Scand J Urol Nephrol. 2011;45:190-195.
24. Chodak GW, Hospelhorn V, Judge SM, et al. Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res. 1988;48:2083-2088.
25. Nguyen M, Watanabe H, Budson AE, et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst. 1994;86:356-361.
26. Fujimoto K, Ichimori Y, Yamaguchi H, et al. Basic fibroblast growth factor as a candidate tumor marker for renal cell carcinoma. Jpn J Cancer Res. 1995;86:182-186.
27. Tsimafeyeu I, Demidov L, Ta H, et al. Fibroblast growth factor pathway in renal cell carcinoma. J Clin Oncol (Meeting Abstr). 2010;28 (suppl 15):4621.
28. Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005;8:299-309.
29. Renhowe PA, Pecchi S, Shafer CM, et al. Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2- ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors. J Med Chem. 2009;52:278-292.
30. Lee SH, Lopes de Menezes D, Vora J, et al. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res. 2005;11:3633-3641.
31. Sarker D, Molife R, Evans TR, et al. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res. 2008;14:2075-2081.
32. Kim KB, Chesney J, Robinson D, et al. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res. 2011;17:7451-7461.
33. Shi MM, Motwani M, Wang J, et al. The pharmacodynamic effect of TKI258 on plasma biomarkers of angiogenesis in patients with AML and advanced melanoma. ASCO Meet Abstr. 2008;26(suppl 15):14680.
34. Angevin E, Lopez-Martin JA, Lin CC, et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res. 2013;19:1257-1268.
35. Angevin E, Grünwald V, Ravaud A, et al. A phase II study of dovitinib (TKI258), an FGFR-and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). J Clin Oncol. 2011;29(suppl): abstract 4551.
36. Motzer RJ, Porta C, Bjarnason GA, et al. Phase III trial of dovitinib (TKI258) versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies. J Clin Oncol. 2012;30(suppl); abstract TPS4683.
37. Cai ZW, Zhang Y, Borzilleri RM, et al. Discovery of brivanibalaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f] [1,2,4] triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem. 2008;51: 1976-1980.
38. Bhide RS, Cai ZW, Zhang YZ, et al. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f] [1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem. 2006;49:2143-2146.
39. Bhide RS, Lombardo LJ, Hunt JT, et al. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther. 2010;9:369-378.
40. Jonker DJ, Rosen LS, Sawyer MB, et al. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Ann Oncol. 2011;22:1413-1419.
41. MckeageMJ, Baguley BC. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer. 2010;116:1859-1871.
42. Chaplin DJ, Horsman MR, Siemann DW. Current development status of small-molecule vascular disrupting agents. Curr Opin Investig Drugs. 2006;7:522-528.
43. Plowman J, Narayanan VL, Dykes D, et al. Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep. 1986;70:631-635.
44. Smith GP, Calveley SB, Smith MJ, et al. Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur J Cancer Clin Oncol. 1987;23:1209-1211.
45. Joseph WR, Cao Z, Mountjoy KG, et al. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res. 1999; 59:633-638.
46. Kremmidiotis G, Leske AF, Lavranos TC, et al. BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. Mol Cancer Ther. 2010;9:1562-1573.